Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

• Patients will receive tamoxifen orally once daily to be taken at home for 1 year. They will be asked to complete a daily drug log to keep track of the pills taken or missed.
• Patients will also be asked to give a blood/DNA sample which will be stored for possible further testing for the presence of cancer related genes that are known nor or discovered in the future.
• Patients will also receive a mammogram that will be reviewed by study officials.
• Side effects will be monitored every 2 months for one year, between visits to the clinic.
• A follow-up visit will be conducted at the 6 month mark and includes a physical exam, blood work, health and wellness surveys)
• A follow-up visit will be performed at the 1 year mark and includes a mammogram, gynecological exam, physical exam, blood work, health and wellness surveys.
• Patients active participation will be for 1 year. However, tamoxifen has been shown to be effective after a 5-year course in other women at increased risk for breast cancer, the patient may decide to stay on tamoxifen for 4 additional years.

Inclusion criteria

• Females diagnosed with Hodgkin's Disease at age < 35 years
• > 5 years from mantle or chest radiation
• Current age > 30 years
• Has completed childbearing
• Willingness to discontinue use of oral contraceptives or other hormonal contraception for duration of the study

Exclusion criteria

• History of secondary malignancy after Hodgkin's disease, except thyroid cancer of basal cell cancer
• Recurrence of Hodgkin's disease in the 5 years before study entry
• Current participation in any other cancer prevention study
• Current or prior use of tamoxifen
• Current use of coumadin
• History of deep venous thrombosis, pulmonary embolism, or a condition known to be associated with hypercoagulability
• History of cerebrovascular accident
• History of macular degeneration
• Current use of chemotherapy for benign disease